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Abstract
Background: Rebiopsy is highly recommended to identify the mechanism of acquired resistance to EGFR-TKIs in
advanced lung cancer. Recent advances in multiplex genotyping based on circulating tumor DNA (ctDNA) provide
a strong and non-invasive alternative for detection of the resistance mechanism.
Case presentation: Here we report a multiple metastatic NSCLC patient who was detected to have pure EGFR 19
exon deletion (negative for EML4-ALK and ROS1 in both IHC-based and sequencing assay) in the primary lesion and
responded to first-line and second-line EGFR-TKI treatments (erlotinib then HY-15772). At 8 months, most lesions
remained well controlled except for the liver metastases which presented dramatic progression. Considering the
high risk of bleeding in rebiopsy of hepatic lesions, we conducted a multiplex genomic profiling with ctDNA.
Results reported coexistence of EGFR mutation and EML4-ALK gene translocation in plasma which heavily indicated
that ALK was the primary reason for progression of the liver lesions. This deduction was supported by the repeated
response to ALK inhibitors (crizotinib then AP26113) of the hepatic metastases.
Conclusions: This is the first report of the existence of ALK rearrangement in metastatic lesions in an EGFR
mutated patient. It highlighted the feasibility and advantages of using ctDNA multiplex genotyping in identifying
the heterogeneity across lesions and the resistance mechanism of targeted treatments.
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Background
Advances in geno-typing have changed the clinical prac-
tice of treatment of non-small cell lung cancer (NSCLC),
especially non-squamous types where driver mutations,
e.g. epidermal growth factor receptor (EGFR) mutations
and echinoderm microtubule-associated protein-like 4-
anaplastic lymphoma kinase (EML4-ALK) translocation
are commonly present. Agents that target EGFR activat-
ing mutations (gefitinib, erlotinib, and afatinib, etc.) or
ALK rearrangement (crizotinib, etc.) derive significantly
greater benefits than cytotoxic chemotherapy in patients
who harbor these gene alterations, which is consistently
proved by extensive large-scale randomized controlled
trials [1, 2]. In order to deliver an appropriate first-line
treatment regimen, detection of EGFR mutation and
ALK rearrangement are recommended as routine gen-
etic profiling for non-squamous NSCLC or non-smoking
populations [3]. In recent years, some selective inhibitors
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that can overcome the resistance to first generation in-
hibitors of these driver alterations have also been devel-
oped, e.g., AZD9291 and CO-1686, some more effective
inhibitors against both EGFR sensitizing and resistance
T790M mutations [4]; or ceretinib, aletinib and
AP26113, the agents that are effective for both ALK fu-
sion and some secondary gatekeeper mutations [5].
Direct sequencing and amplification refractory mutation
system (ARMS)-PCR are the common testing methods for
EGFR mutations. FISH, RT-PCR and Ventana IHC are all
currently accepted methods for detection of ALK re-
arrangement. In recent years, the development and ad-
vances in high throughput next-generation sequencing
(NGS) have allowed the simultaneous profiling of alter-
ations in multiple genes [6]. Circulating tumor DNA
(ctDNA) is released or excreted by tumour cells and
circulates in the blood of a cancer patient; analysis of the
fraction of mutant-alleles from ctDNA compared to
normal-alleles from the patients’ normal genome provides
opportunities for minimally-invasive cancer diagnosis and
tumor monitoring [7]. Detection with ctDNA, which orig-
inates from all potential lesions, could overcome the dis-
advantages of single site biopsy given that the intra-
tumoral and inter-lesional heterogeneity is common [6, 8].
Enrichment of plasma ctDNA and incorporation with the
next generation deep sequencing techniques allow us to
simultaneously detect the gene alterations of interest, e.g.
EGFR/BRAF/HER2 mutations, ALK/ROS1/RET rear-
rangements, MET amplification, etc. in NSCLC, especially
when it is difficult to obtain sufficient tissue samples.
EGFR mutations and ALK rearrangement are generally
considered to be mutually exclusive. However, some re-
cent surveys and case reports showed co-existence of
the two alterations within the same lesion [9, 10]. Here,
we report an advanced NSCLC case with EGFR exon 19
deletion who experienced single-site progression in the
liver after primary response to EGFR-TKI treatments
and showed good response when adding crizotinib after
the detection of ALK rearrangement signal through
ctDNA. This special case highlights the feasibility and
necessity of using ctDNA multiplex genomic profiling as
an alternative approach in molecular diagnosis of
NSCLC or in the exploration of the underlying mechan-
ism in resistance to targeted therapies. Moreover, it en-
courages us to re-evaluate the heterogeneity across
lesions of metastatic NSCLC.
Case Presentation
A 46-year-old woman with stage IVb lung adenocarcin-
oma of the left upper lobe and extensive metastases
(mediastinal lymph nodes, bilateral lung, liver, brain,
multiple vertebrae, pelvis, adrenal glands, retroperiton-
eal lymph nodes, etc.) was confirmed to harbor EGFR
19 exon deletion by ARMS-PCR. She was negative for
EML4-ALK and ROS1 by ventana IHC staining. Evalu-
ation after 1 month and 3 months of erlotinib 150 mg
Qd treatment showed good partial response across all le-
sions. However, the patient presented with severe short-
ness of breath after 4 months. CT scan showed rapid
progression of the distributed pulmonary and hepatic le-
sions. Based on the imaging features and clinical symp-
toms, it was initially difficult to differentiate whether the
patient had interstitial pneumonia due to erlotinib, or
lymphangitis carcinomatosa. Thus, we firstly withdrew er-
lotinib and delivered methylprednisolone pulse therapy
(500 mg qd * 5 days). However, no improvement was ob-
served, which lead us to the diagnosis of lymphangitis car-
cinomatosa due to disease progression. Pemetrexed 0.8 g
plus bevacizumab 300 mg (the tumor board decided to
use a platinum-free regimen due to low tolerance to plat-
inum of this patient, ECOG performance score 2–3), was
then administered, but the lesions continued to grow rap-
idly. Noninvasive positive pressure ventilation was applied
when the patient experienced type I respiratory failure.
The patient took HY-15772, an active pharmaceutical in-
gredient (API) that was known for AZD9291, 100 mg qd
on her own volition. She recovered from hyoxemia grad-
ually and CT review showed tumor remission at 1 week
after starting HY-15772 API. The patient continued to
take HY-15772 API for 2 months. CT-scan showed that
all lesions were controlled except for the liver metastases
in the left lobe which underwent dramatic bulky progres-
sion. Multidisciplinary consultation suggested that a nee-
dle biopsy of the liver lesions was not preferable due to
the high risk of procedure-related bleeding. Thus, we de-
cided to obtain peripheral blood for ctDNA multiplex
genotyping analysis using the capture probe baits sequen-
cing platform (methods and gene list were provided in
Additional file 1). Meanwhile, a dose of gemcitabine
chemotherapy 1.4 g on day 1 and day 8 was administered.
During the intermission, the ctDNA analysis reported the
existence of both EGFR 19 exon L747S non-shifting dele-
tion (abundance 48.5 %) and EML4-ALK rearrangement
(abundance 10.09 %) in the plasma (No other druggable
alteration was found especially in domains of MET).
Upon the second cycle the gemcitabine chemotherapy,
the patient complained of an obvious sensation of mass
in the upper abdomen and the inability to keep food or
drink down. We suggested the patient add crizotinib
and continue HY-15772 API. After 5 days of additional
crizotinib treatment, the patient was able to drink and
eat and had the sensation of mass shrinkage. CT scan
after 1 month reavealed significant remission of the le-
sions in the left lobe of the liver (plasma ALK abun-
dance decreased to 2.79 %). After 2 months of
crizotinib, liver metastases especially those in the left
lobe again progressed, which was manifested as abdom-
inal distention and edema of bilareal lower extremity
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(plasma ALK abundance increased to 14.59 %). The pa-
tient switched the ALK inhibitor to AP26113 API at a
dose of 180 mg Qd on her own volition and quickly
regained good remission of the hepatic lesions (plasma
ALK abundance decreased to 0.00 %). In addition,
plasma ALK fusion was not detected. Figure 1
Fig. 1 Changes in image during treatments. API, active pharmaceutical ingredient
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illustrated the change of the image presentation and
treatments. Upon submission of this report, the patient
is still receiving a combination treatment of HY-15772
and AP26113 API without any signs of disease worsen-
ing. Re-analysis of the biopsy tissue from the primary
lesion through the same multiplex genomic platform
showed pure EGFR exon 19 deletion without any signal
for EML4-ALK fusion. In addition, repeated analyses
indicated the presence of TP53 Y236D mutations in 7
exon with more than 50 % abundance. Figure 1 illus-
trated the flow of treatments and image evaluation.
Discussions
The current recommendation for management of single-
site regional progression in resistance to EGFR-TKIs is to
perform localized therapies and rebiopsy when available
[11]. In this case, the progressed liver metastases were
large, bulky, and scattered. Radiotherapy or radiofre-
quency ablation was not an appropriate option. Metastatic
hepatic lesions were supplied by portal vein system rather
than hepatic artery system. Thus, transcatheter arterial
chemoembolization (TACE) might not derive significant
benefits. On the other hand, this case progressed dramat-
ically after showing resistance to EGFR-TKIs. In this case,
switching to chemotherapy is suggested according to what
IMPRESS trial indicated [12]. Considering the previous
evidence of the patients’ insensitivity to pemetrexed, we
decided to use gemcitabine single agent chemotherapy.
Meanwhile, we continued the use of HY-15772 API since
all extra-hepatic lesions remained stable or even undetect-
able in the images, which suggested these lesions
remained sensitive to HY-15772 API.
Rebiopsy was another issue worth clarifying. In this case,
as the entire left lobe of the liver was occupied by meta-
static lesions that were loosened in structure, multidiscip-
linary consultation opinions suggested that conducting a
fine-needle biopsy would be dangerous due to the high
risk of bleeding. Recent advances in non-invasive rebiopsy
approaches such as multiplex genomic profiling of ctDNA
provided us an alternative [13]. We decided to obtain
peripheral blood from this patient to perform a NSCLC-
related multiplex genotyping, in order to clarify the resist-
ance mechanism. Surprisingly, in addition to the 19del
EGFR mutation that was previously discovered in the
primary lesion, EML4-ALK fusion with relatively high
abundance in plasma was detected. Given that the extra-
hepatic lesions were all under control, indicating their
lasting response to HY-15772 API, we added Crizotinib,
the only approved agent to inhibit ALK-driving tumors, to
the regimen without withdrawing the EGFR suppressor.
Previous reports suggested no significant superimposed
toxicity in dual treatment with EGFR and ALK inhibitors
[14]. In this case, the patient presented rapid relief without
any grade III adverse events. Undoutedly, the timely
addition of ALK inhibitors salvaged the patient as previous
gemcitabine showed no efficacy.
Though some previous studies reported co-existence
of EGFR and ALK in the same lesions, this is the first
report showing ALK rearragement in distant meta-
static lesions in a patient potentially harboring pure
EGFR mutations in the primary lesion. Since rebiopsy
for the liver metastases in the left lobe was not an op-
tion in this case, we had no direct evidence that the
liver progression was driven by ALK fusion. However,
the great abundance of EML4-ALK fusion signals in
the plasma upon disease progression and the signifi-
cant response after adding crizotinib (as well as the
AP26113 API after resistance to crizotinib) strongly
supported the existence of ALK fusion in the growing
liver metastases. In addition, it was not likely that the
primary lesion harbored concurrent EGFR mutation
and ALK fusion because both routine ARMS and NGS
re-analysis showed that no ALK fusion was detected
and the pulmonary lesions were all in good control by
HY-15772 API when the hepatic metastases pro-
gressed. Such heterogeneity might be more common
than we have previously acknowledged, and might
have a great impact on treatment strategy. In the past,
we could only detect genetic alterations with site by
site tissue samples. It was too difficult to obtain tissues
from all lesions; multiplex genotyping with ctDNA
might help address this issue. Thus, with the current
technology, we should reevaluate the heterogeneity
across different lesions and their incidence. Of course,
the sensitivity of ctDNA examination and the substan-
tial validation require further efforts.
We cannot determine whether the ALK fusion was in-
herent or if it was an evolvement after treatment. One
possibility is the clonal selection mechanism, EML4-ALK
fusion emerged when EGFR mutations were suppressed.
However, in both the treatment with erlotinib and subse-
quent HY-15772 API, the hepatic lesions showed good re-
sponse to these EGFR-TKIs, which suggested no or
minimal ALK fusion at that point. But some reports have
also revealed responsiveness to EGFR-TKIs in patients
with ALK fusion or dual alterations [15]. Another poten-
tial reason is the inducement or de novo activation of
EML4-ALK fusion after EGFR-TKI treatments since re-
peated analyses showed consistent high abundance (over
50 %) of TP53 mutation which heavily indicated to the
presence of loss of heterozygosity (LOH) phenomena [16].
Genome instability might increase the risk for inducing
other driver gene altrations. Further studies on the mech-
anism is warranted.
Conclusions
In conclusion, this is the first report of the existence of
ALK rearrangement in metastatic lesions in an EGFR
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mutated patient. It highlighted the feasibility and advan-
tages of using ctDNA multiplex genotyping in identifying
the resistance mechanism of targeted treatments. Further
well designed studies on its true effectiveness and criteria
for elegible patient selection are warranted. In addition,
ctDNA multiplex genotyping could benifit us in studying
the heterogeneity across lesions of lung cancer.
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